RASSF8 and non-small cell lung carcinoma: miR-30c and miR-21 fostered proliferation and reduced response to cisplatin by targeting BID and RASA141,42 while promoted invasive capabilities and EMT of NSCLC cells through RASA1, NF1, and RASSF8 downregulation.